Noxopharm (ASX:NOX) - Chief Medical Officer, Gisela Mautner
Chief Medical Officer, Gisela Mautner
Source: Noxopharm
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Noxopharm (NOX) is planning to extend the trials of its COVID-19 treatment after receiving positive preliminary results from its phase one clinical trial
  • NOX tested its anti-inflammatory drug in COVID-19 patients with moderate versions of the virus to see if the treatment could stop patients worsening
  • The company says that pleasingly, 37 of the 38 patients tested completed their treatment of NOX’s Veyonda drug and were discharged
  • Noxopharm is in discussion for the treatment to be used in funded clinical trial platforms, with full data from the phase one trial to be released soon
  • Shares in NOX are trading up 6.31 per cent at 59 cents per share at 11:28 am AEST

Noxopharm (NOX) is planning to extend the trials of its COVID-19 treatment after receiving positive preliminary results from its phase one clinical trial.

The drug-development company recently tested its anti-inflammatory drug on COVID-19 patients with moderate versions of the virus.

The goal was to see whether Veyonda could stop patients’ conditions worsening by suppressing a self-harming inflammatory response to damaged lung tissue without compromising a protective immune response.

NOX said that pleasingly, 37 of the 38 patients who were tested using the drug completed their treatment and were discharged.

Only one patient had to be ventilated after their COVID-19 symptons worsened and this patient later died from the virus.

Noxopharm CEO and Managing Director Graham Kelly said the results were very encouraging.

“No major safety issues were identified in the trial, and the recovery of 37 of 38 patients rated as having moderate disease requiring hospitalization and supplementary oxygen for the majority of patients, can be described as highly encouraging,” Dr Kelly said.

The MD added that Veyonda could be used both in-hospital and as outpatient management.

“Our target patients are those with a moderate degree of pneumonia experiencing breathing difficulties,” Dr Kelly said.

“Behind this pneumonia is an inappropriately excessive inflammatory response to the presence of the virus in the lungs.

“The objective is to use Veyonda to dampen that inflammatory response before it escalates to the point of triggering an even greater inflammatory response that can go on to cause even more widespread tissue damage.”

Following the positive preliminary results, Noxopharm is now in discussion for the treatment to be used in funded clinical trial platforms.

The company is also expecting the full data from the phase one clinical trial to be released in the coming weeks.

Shares in Noxopharm were trading up 6.31 per cent at 59 cents per share at 11:28 am AEST.

NOX by the numbers
More From The Market Herald

" Resonance Health (ASX:RHT) contracted for third party liver disease study

Resonance Health (ASX:RHT) has been contracted to provide liver-fat quantification services for a clinical study to…

" Cann Group (ASX:CAN) granted GMP licence by TGA

Cann Group (ASX:CAN) receives a GMP licence from the Therapeutic Goods Administration (TGA) to manufacture therapeutic…
1st Group (ASX:1ST) - Managing Director, Klaus Bartosch

" 1st Group (ASX:1ST) shares rise on Visionflex acquisition

Digital health company 1st Group (ASX:1ST) was up as much as 25 per cent on the…
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars

Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars